Repligen Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Repligen wird ein jährliches Gewinn- und Umsatzwachstum von 38.3% bzw. 13.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 39.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 5% betragen.

Wichtige Informationen

38.3%

Wachstumsrate der Gewinne

39.7%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	16.2%
Wachstumsrate der Einnahmen	13.8%
Zukünftige Eigenkapitalrendite	5.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03

Recent updates

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Jun 14

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Jun 10

Repligen Stock: Still Quite Overvalued

May 30

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Sep 29

Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Aug 09

Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Jul 17

Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

Jul 03

With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Jun 19

Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

May 23

Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Apr 11

Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

Mar 28

We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Mar 08

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Feb 20

Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Jan 10

Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?

Dec 28

Is Repligen (NASDAQ:RGEN) A Risky Investment?

Oct 03

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:RGEN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	851	128	168	201	6
12/31/2025	738	87	117	177	13
12/31/2024	639	44	88	145	14
3/31/2024	607	15	110	147	N/A
12/31/2023	639	42	75	114	N/A
9/30/2023	670	116	97	147	N/A
6/30/2023	729	138	51	149	N/A
3/31/2023	778	168	46	160	N/A
12/31/2022	802	186	39	172	N/A
9/30/2022	801	166	15	160	N/A
6/30/2022	779	159	41	141	N/A
3/31/2022	734	146	42	133	N/A
12/31/2021	671	128	48	119	N/A
9/30/2021	593	119	35	84	N/A
6/30/2021	509	100	40	83	N/A
3/31/2021	433	80	32	62	N/A
12/31/2020	366	60	36	63	N/A
9/30/2020	327	44	44	65	N/A
6/30/2020	302	31	42	66	N/A
3/31/2020	286	23	43	67	N/A
12/31/2019	270	21	44	67	N/A
9/30/2019	253	23	34	55	N/A
6/30/2019	233	27	34	53	N/A
3/31/2019	210	21	25	41	N/A
12/31/2018	194	17	19	33	N/A
9/30/2018	184	23	32	42	N/A
6/30/2018	171	23	14	21	N/A
3/31/2018	155	29	12	18	N/A
12/31/2017	141	28	N/A	17	N/A
9/30/2017	125	21	N/A	4	N/A
6/30/2017	113	18	N/A	5	N/A
3/31/2017	110	13	N/A	12	N/A
12/31/2016	105	12	N/A	8	N/A
9/30/2016	100	7	N/A	9	N/A
6/30/2016	96	8	N/A	17	N/A
3/31/2016	88	8	N/A	14	N/A
12/31/2015	84	9	N/A	15	N/A
9/30/2015	78	9	N/A	13	N/A
6/30/2015	74	8	N/A	13	N/A
3/31/2015	68	7	N/A	8	N/A
12/31/2014	64	8	N/A	18	N/A
9/30/2014	63	12	N/A	24	N/A
6/30/2014	66	16	N/A	24	N/A
3/31/2014	68	18	N/A	30	N/A
12/31/2013	68	16	N/A	26	N/A
9/30/2013	72	22	N/A	26	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RGENDas prognostizierte Gewinnwachstum (38.3% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: RGENDie Erträge des Unternehmens (38.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: RGENEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: RGENDie Einnahmen des Unternehmens (13.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: RGENDie Einnahmen des Unternehmens (13.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RGENDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (5%).

Repligen Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 10%

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

Consensus EPS estimates fall by 45%

Price target increased by 8.2% to US$205

Repligen Corporation Provides Earnings Guidance for the Year 2024

Recent updates

Now 20% undervalued after recent price drop

Repligen Corporation Announces CEO Changes, Effective September 1, 2024

Repligen Corporation Announces Management Changes, Effective September 1, 2024

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Now 20% undervalued after recent price drop

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

Repligen Stock: Still Quite Overvalued

CEO & Director recently sold US$3.4m worth of stock

CEO & Director notifies of intention to sell stock

Consensus EPS estimates increase by 10%

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

New minor risk - Earnings quality

First quarter 2024 earnings: EPS misses analyst expectations

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen Corporation to Report Q1, 2024 Results on May 01, 2024

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Repligen Corporation, Annual General Meeting, May 16, 2024

Repligen Corporation Appoints Maggie A. Pax as Board of Directors

CEO & Director recently sold US$3.3m worth of stock

CEO & Director notifies of intention to sell stock

Consensus EPS estimates fall by 45%

Chief Operating Officer recently sold US$680k worth of stock

Chief Operating Officer notifies of intention to sell stock

Price target increased by 8.2% to US$205

Repligen Corporation Provides Earnings Guidance for the Year 2024

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Repligen Corporation to Report Q4, 2023 Results on Feb 21, 2024

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Repligen Corporation announced that it has received $290.1 million in funding

Repligen Corporation announced that it expects to receive $290.1 million in funding

Repligen Corporation announced that it expects to receive $290.1 million in funding

Insider recently sold US$557k worth of stock

Consensus EPS estimates increase by 16%

Repligen Corporation Launches TangenX®? SC as First-To-Market Holder-Free Self-Contained TFF Device

Price target decreased by 7.6% to US$179

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2023

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Third quarter 2023 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 16%

Repligen Corporation to Report Q3, 2023 Results on Oct 31, 2023

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Repligen Corporation Appoints Olivier Loeillot as President and Chief Commercial Officer

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Repligen Corporation (NasdaqGS:RGEN) entered into a definitive agreement to acquire Metenova AB.

Now 23% undervalued

Repligen Corporation Appoints Jason K. Garland as Chief Financial Officer Effective September 25, 2023

Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification

Now 20% undervalued

Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Consensus revenue estimates fall by 11%

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 17%

Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)

Insider recently bought US$238k worth of stock

Consensus EPS estimates fall by 16%

First quarter 2023 earnings: EPS exceeds analyst expectations

Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly

Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?

We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease

Consensus EPS estimates fall by 17%

Chief Financial Officer recently sold US$1.1m worth of stock

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)